Home
Charts
Search
Watchlist
Products
All IPOs
₹90 - 90
Modern Diagnostic & Research Centre Ltd
HealthcareIPOSME
₹90 - 90
The Company is a services provider in diagnostic and related healthcare tests services in India. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory. Through its integrated, nationwide network, the company offers a complete range of diagnostic facilities in radiology and pathology. The Company provides healthcare tests and services for use in core testing, patients' diagnosis and prevention, monitoring of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
Lot1,600Min Invest₹2,88,000Face Value₹10Issue Size₹37 CrFresh Issue₹37 CrListing Price₹100CMP₹60
Timeline
31 Dec
Bidding opens
2 Jan
Bidding closes
5 Jan
Allotment
6 Jan
Refund & demat credit
7 Jan
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹37 Cr0.41 Cr shares
Fresh Issue₹37 Cr
Face Value₹10
Lot Size1,600 shares
ReservationQIB 49.94% · NII 15.04% · RETAIL 35.02%
Application Sizes
Retail₹2,88,0001-1 lots
sNII₹2,88,000from 2 lots
bNII₹10,08,000from 7 lots
Managers & Registrar
Lead ManagerBeeline Capital advisors Pvt Ltd
RegistrarMUFG Intime India Pvt Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group100%72.85%Public0%27.15%
Objects of the Issue
- Funding capital expenditure for purchase of medical Equipments for diagnostic centre and laboratories
- Funding working capital requirement
- Repayment of certain outstanding borrowings availed by the company
- General corporate expenses
Financials
Profit & Loss
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| RevenueCr | 60 | 56 | 67 | 78 | 83 |
| Operating ProfitCr | 6 | -1 | 11 | 18 | 13 |
| OPM% | 9.9 | -1.8 | 16.5 | 23.2 | 15.2 |
| PBTCr | 1 | -6 | 7 | 13 | 6 |
| PATCr | -1 | -6 | 6 | 9 | 5 |
| EPS | -1 | -5 | 5 | 8 | 3 |
Balance Sheet
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity CapitalCr | 1 | 1 | 1 | 11 | 15 |
| ReservesCr | 11 | 5 | 11 | 10 | 43 |
| BorrowingsCr | 20 | 15 | 20 | 22 | 37 |
| Total AssetsCr | 49 | 37 | 49 | 65 | 119 |
Cash Flow
| Financial Year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Operating Cash FlowCr | 4 | 0 | 8 | 14 | 4 |
| Investing Cash FlowCr | -5 | 2 | -11 | -13 | -40 |
| Financing Cash FlowCr | 5 | -6 | 3 | 0 | 45 |
| Net Cash FlowCr | 3 | -4 | 0 | 0 | 9 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced Promoter and Management Team.
- Comprehensive diagnostics provider delivering all-in-one solution at cost-effective prices.
- Focus on quality and customer service.
- Centralized information technology platform.
Strategies · as stated in the DRHP
- Leveraging its market skills and relationship.
- Continue its Focus on Providing Quality Tests and Services.
- Expand its geographical presence.
- Increase the breadth of its diagnostic healthcare testing and services platform.
Risks · as stated in the DRHP
- Any interruptions at its laboratories and diagnostic centres may affect the company's ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.
- The company's business and prospects may be adversely affected if the company is unable to maintain and grow its brand name and brand image.
- Majority of the company's operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on its business, results of operations and financial condition.
- The company has certain outstanding litigation against us, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failures of which could result in serious service disruptions.
- The company's heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact its operations, financial performance, and long-term growth prospects.